DoW Ovarian Cancer, Clinical Trial Award
Defense Health Agency Contracting Activity - DHACA · Military Medical Research and Development (12.420)
Posted 4 May 2026 · Closes today
In plain terms
The US Defense Health Agency funds clinical trials to evaluate new treatments, drugs, devices and approaches for ovarian cancer management, from proof-of-concept to large-scale efficacy studies. Any type of US organisation or individual may apply; the total programme budget is 5.6 million US dollars and applications are due by 1 October 2026.
A generated summary of the donor's text; the original wording is below.
Summary
Summary: The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer.
Distinctive Features: Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.
Excerpt from the donor's page. The full text, annexes and forms are on the original call.
Who can apply
- ngo_cso
- community_based_org
- government
- academia_research
- private_company
- social_enterprise
- individual
- un_agency
- other
Eligibility and conditions
Show the eligibility text from the source
Applicant types: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"